Abstract: A stilbene glycoside (resvebassianol A) (1) with a unique sugar unit, 4-O-methyl-D-glucopyranose, was identified through biotransformation of resveratrol (RSV) by the entomopathogenic fungus *Beauveria bassiana* to obtain a superior RSV metabolite with enhanced safety. Its structure, including its absolute configurations, was determined using spectroscopic data, HRESIMS, and chemical reactions. Microarray analysis showed that the expression levels of filaggrin, HAS2-AS1, and CERS3 were higher, while those of IL23A, IL1A, and CXCL8 were lower in the resvebassianol A-treated group than in the RSV-treated group, as confirmed by qRT-PCR. Compound 1 exhibited the same regenerative and anti-inflammatory effects as RSV with no cytotoxicity in skin keratinocytes and cell signaling pathways and diseases associated with oxidative stress, inflammation, cancer, abnormal metabolism, and neurotoxicity [3].

To date, the clinical effects of RSV have not been sufficiently validated in cellular and animal studies. Additionally, there have been some limitations to its commercialization. For example, RSV is well absorbed in vivo, but it is rapidly metabolized to sulfo- or glucuron conjugates [4]. RSV is safe at low doses, but it may have poor bioavailability in humans due to extensive hepatic metabolism [5]. Therefore, developing a drug for clinical use using RSV has been challenging. To overcome these problems, a new micronized RSV formulation—SRT 501—has been developed [6]. However, limitations associated with the metabolism and bioavailability of RSV continue to exist, and there is a need for RSV-derived compounds with enhanced bioavailability.
Natural product drug discovery includes the process of diverting more active molecules from the original active molecules of natural products, wherein a microbial transformation is a useful approach. The use of specific microorganisms that mimic mammalian metabolism to perform selective transformation reactions is advantageous due to the economically and ecologically friendly microbial transformations [7]. Attempts have been made to produce new RSV compounds using biotransformation and biosynthesis of RSV by microorganisms. A simple method to efficiently produce RSV from polydatin (piceid) using Bacillus safensis has been reported [8]. Owing to the practical challenges during the microbial production of RSV, some studies have been conducted on fungal strains such as Botrytis cinerea, which oxidizes RSV to produce RSV dimers such as resrytisols A, B, and C [9]. RSV 3-O-β-D-glucoside has also been produced from RSV using Bacillus cereus, also known as soil bacteria [10]. Additionally, the biotransformation technique using Aspergillus sp. yielded a new prenylated trans-RSV (arahypin-16) and RSV trans-dehydrodimer (leachinol F) [11]. However, their biological activities are not superior to those of RSV. In our preliminary experiments, biotransformation studies were performed using several dietary Lactobacillus and fungi. Interestingly, among them, it was confirmed that newly produced substances were detected only when the experiment was performed using Beauveria bassiana. Therefore, to obtain superior RSV metabolites with enhanced safety using microbial co-culture, we co-cultured RSV with tissue culture seedlings of B. bassiana, which is an important entomopathogenic fungus currently under development as a bio-control agent for various insect pests [12]. In the present study, resvebassianol A, a stilbene glycoside with a unique sugar unit, 4-O-methyl-D-glucopyranose, was isolated from the whole-cell fermentation of B. bassiana. The bio-functional superiority of the newly produced RSV metabolite, resvebassianol A, through biotransformation of RSV by B. bassiana, was further investigated using microarray analysis.

2. Materials and Methods

2.1. Microorganism

Beauveria bassiana (KCCM 60248) was purchased from the Korean Culture Center of Microorganisms (Seoul, Korea). All culture and biotransformation experiments were performed in potato dextrose agar (PDA, BD, Le Pont-de-Claix, France).

2.2. Metabolites of RSV Manufactured by B. bassiana

B. bassiana was incubated in PDA (0.4% potato starch, 2% dextrose, and 2% agar) at 26 °C for 3 days, and subsequently, the spores were collected from the plate surface using 0.85% saline and gauze filtration. The RSV metabolites were produced at different time points (0, 1, 3, and 7 days) at 26 °C for 72 h in a 100 rpm shaking incubator with initial inoculation concentrations of 5 × 10⁷ spores/mL and RSV concentration of 100 µg/mL in the culture medium. The culture medium was treated with a two-fold volume of ACN, and it was vortexed, sonicated, and centrifuged at 8000 rpm for 15 min. The supernatants were filtered using a 0.2 µm syringe. The filtrate was concentrated and chromatographically analyzed using HPLC.

2.3. HPLC Analysis of RSV Metabolites

RSV metabolites were analyzed using a reverse-phase HPLC system (Waters Corp., Milford, MA, USA) with a photodiode array detector (model 2998, Waters Corp.) and a SunFire™ analytical C18 column (4.6 × 150 mm, 5 µm, Waters Corp.). The solvent system consisted of a gradient of solvent A (water:tetrahydrofuran:trifluoroacetic acid, 98:2:0.1, v/v/v) and solvent B (MeCN) with an initial composition of 83% A, isocratic to 75% A from 2 to 7 min, linear gradient to 65% A from 7 to 15 min, linear gradient to 50% A from 15 to 20 min, linear gradient to 20% A from 20 to 35 min, linear gradient to 83% A from 35 to 40 min, and linear gradient to 83% A from 40 to 45 min. Following this, the column was washed and reconditioned. The solution was eluted at a flow rate of 1 mL/min, and the UV spectra were monitored at 305 nm.
2.4. Isolation of RSV Metabolites

To optimize the incubation time, the culture medium was harvested after 1, 3, and 7 days, and the biotransformation yields were monitored at each time point. After a day of incubation, the RSV metabolite reached its maximum yield. The fermentation broth was extracted using a two-fold volume of MeCN, and it was vortexed, sonicated, and filtered. The filtrate was concentrated to yield the MeCN soluble fraction, which was purified by semi-preparative HPLC using a Phenomenex Luna phenyl-hexyl column (250 × 10 mm i.d., flow rate: 2 mL/min) with a solvent system containing 40% MeOH/H$_2$O to yield compounds 1 (t$_R$ 15.5 min, 2.1 mg) and 2 (t$_R$ 34.0 min, 0.4 mg).

Resvebassianol A (1)

White amorphous powder; [α]$_D^{25}$ −47.3 (c 0.1, MeOH); IR (KBr) ν$_{max}$ 3039, 2866, 1551, 1210, 1076 cm$^{-1}$; UV (MeOH) λ$_{max}$ (log ε) 210 (2.4), 305 (4.0) nm; $^1$H (700 MHz) and $^{13}$C NMR data, see Table 1; HRESIMS (negative-ion mode): m/z 403.1395 [M–H]$^-$ (calcd. for C$_{21}$H$_{23}$O$_8$, 403.1393).

Table 1. $^1$H (700 MHz) and $^{13}$C NMR (175 MHz) Data of Resvebassianol A (1) in CD$_3$OD.

| Position | δ$_H$ (ppm) | δ$_C$ (ppm) |
|----------|-------------|-------------|
| 1        | 141.0       |             |
| 2        | 6.46 d (2.0) | 106.0       |
| 3        |             | 159.8       |
| 4        | 6.18 t (2.0) | 103.1       |
| 5        |             | 159.8       |
| 6        | 6.46 d (2.0) | 106.0       |
| 1$'$     |             | 133.2       |
| 2$'$     | 7.45 d (8.5) | 128.7       |
| 3$'$     | 7.07 d (8.5) | 118.0       |
| 4$'$     |             | 158.8       |
| 5$'$     | 7.07 d (8.5) | 118.0       |
| 6$'$     | 7.45 d (8.5) | 128.7       |
| 1$''$    | 6.88 d (16.0)| 128.7       |
| 2$''$    | 6.99 d (16.0)| 129.1       |
| 1$'''$   | 4.90 d (8.0) | 102.2       |
| 2$'''$   | 3.47 dd (9.0, 8.0) | 75.1 |
| 3$'''$   | 3.57 t (9.0) | 78.1       |
| 4$'''$   | 3.21 t (9.0) | 80.7       |
| 5$'''$   | 3.43 ddd (9.0, 5.0, 2.0) | 77.3 |
| 6$'''$   | 3.71 dd (12.0, 5.0); 3.86 dd (12.0, 2.0) | 62.2 |
| 4$'''$-OCH$_3$ | 3.59 s       | 61.1       |

*Signal multiplicity is expressed as doublet (d), doublet of doublet (dd), doublet of doublet of doublet (ddd), and triplet (t) and coupling constants (Hz) are in parentheses.

2.5. Acid Hydrolysis of 1

Compound 1 (1.0 mg) was hydrolyzed using 1 mL of 1N HCl under reflux conditions at 90 °C for 1 h. The hydrolysate was diluted with H$_2$O, extracted using CH$_2$Cl$_2$ (3 × 2 mL), and the extract was evaporated in a vacuum to yield the aglycone, RSV (0.3 mg), which was identified using $^1$H NMR [13] and LC/MS analysis. The aqueous layer was neutralized by passing it through an Amberlite IRA-67 column (Rohm and Haas, Philadelphia, PA, USA), and it was repeatedly evaporated to yield the sugar unit 4-O-methyl-D-glucopyranose (0.4 mg, [α]$_D^{25}$ +27.5 (c 0.02, MeOH)).

2.6. Microarray

RNA labeling and hybridization were conducted in accordance with the Agilent One-Color Microarray-Based Gene Expression Analysis protocol (Agilent Technologies, V 6.5, 2010, Lexington, MA, USA). Briefly, 200 ng of total RNA from each sample was linearly amplified, and it was labeled with Cy3-dCTP. The labeled cRNAs were purified
using an RNeasy Mini Kit (Qiagen, Hilden, Germany). The concentrations and specific activities of labeled cRNAs (pmol Cy3/µg cRNA) were measured using NanoDrop ND-1000 (NanoDrop, Wilmington, NC, USA). Subsequently, 600 ng of each labeled cRNA was fragmented by adding 1 µL of 25 × fragmentation buffer and 5 µL 10 × blocking agent, and they were heated at 60 °C for 30 min. Finally, 25 µL 2 × GE hybridization buffer was added to dilute the labeled cRNA. Following this, 50 µL of hybridization solution was dispensed into the gasket slide, and it was placed in the SurePrint G3 Custom Gene Expression Microarrays, 8 × 60 K (Agilent Technologies). The slides were incubated at 65 °C for 17 h in an Agilent hybridization oven and washed at room temperature according to the Agilent One-Color Microarray-Based Gene Expression Analysis protocol (Agilent Technology, V 6.5, 2010). The hybridized array was immediately scanned using an Agilent SureScan Microarray Scanner (Agilent Technologies).

2.7. Cell Culture

HIEC-6, human small intestinal cells (ATCC, Manassas, VA, USA), were maintained in OptiMEM (Gibco, Waltham, MA, USA), 4% fetal bovine serum (FBS), 20 mM HEPES, 10 mM GlutaMAX, 10 ng/mL epidermal growth factor, 100 U/mL penicillin, and 100 µg/mL streptomycin. HaCaT cells, spontaneously immortalized human keratinocyte cells, were obtained from the Korean Cell Line Bank. Cells were cultured in Dulbecco’s modified eagle medium (HyClone) supplemented with 10% FBS, 100 U/mL penicillin, and 100 µg/mL streptomycin. Subsequently, cells were incubated in a humidified atmosphere of 5% CO₂ at 37 °C.

2.8. Cell Viability

To measure the cytotoxicity of compound 1 using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, HIEC-6, and HaCaT cells were seeded in a 48-well plate (3 × 10⁴ cells/well) and incubated for 24 h. Subsequently, the cells were treated with different doses of resvebassianol A and RSV for 24 h. After treatment, the cells were incubated with MTT solution (0.5 mg/mL, Sigma-Aldrich, St. Louis, MO, USA) at 37 °C for 1 h. The dark blue formazan crystals were solubilized using 200 µL of DMSO per well, and the absorbance was measured at 570 nm using a spectrophotometer (Molecular Devices, San Jose, CA, USA).

2.9. Enzyme-Linked Immunosorbent Assay (ELISA)

Interleukin (IL)-6 and IL-1β levels were measured using ELISA. HIEC-6 and HaCaT cells were seeded (3 × 10⁵ cells/well) in a 24-well plate and stimulated using TNF-α and INF-γ (10 ng/mL each) in the presence of compound 1 and RSV. After 24 h of incubation, the supernatants were collected, and the levels of IL-1β and IL-6 were evaluated using their respective ELISA kits (R&D Systems, Minneapolis, MN, USA).

2.10. Cell Proliferation and Migration Assay

Cell proliferation was analyzed using the 5-Bromo-2-deoxyUridine (BrdU) assay. Briefly, HaCaT cells were seeded in a 24-well plate (4.0 × 10⁴ cells/well), treated with compound 1 or RSV for 24 h or 48 h with or without IL-22 (50 ng/mL) stimulation, and incubated with a final concentration of 10 µM BrdU. After incubation, cells were fixed at room temperature for 30 min, incubated with peroxidase-linked BrdU-antibody for 1 h, washed three times, incubated with HRP-conjugated antibody for 30 min, washed three times, and incubated with 3,3′,5,5′-tetramethylbenzidine solution for 30 min. Subsequently, the absorbance was measured at 450 nm. To measure the cell migration rates, cells were seeded at a density of 3.0 × 10⁴ cells per well in 96-well ImageLock plates (Essen Bioscience, Arbor, MI, USA) and incubated to form a spatially uniform monolayer. Scratch wounds were created in monolayers of cultured cells using a Wound Maker™ (Essen Bioscience). After creating the scratch wound, cells were washed twice with phosphate-buffered saline, incubated with or without IL-22, and treated with compound 1 or RSV in fresh serum-free
media. The plate was placed in an IncuCyte® ZOOM (Essen Bioscience), and the migrating cell images were recorded after 6 h of wound creation.

2.11. Statistical Analysis

Results of the statistical analyses are expressed as mean ± SEM. Statistical comparisons were made between the control and other groups by Bonferroni’s test for multiple comparisons of one-way analysis of variance using the GraphPad Prism 5.0 software (GraphPad Software Inc., San Diego, CA, USA). A p-value less than 0.05 indicated statistical significance.

3. Results and Discussion

3.1. Identification of RSV Metabolite with 4-O-Methyl-D-Glucopyranose through Biotransformation by Beauveria bassiana

To investigate the metabolite profile of RSV obtained from biotransformation using B. bassiana, RSV was incubated in the culture medium with B. bassiana for 0, 1, 3, and 7 days. The medium samples were analyzed using HPLC, where the concentration of RSV significantly decreased with increasing incubation time, which indicates the bio-conversion of RSV (Figure S1 (Supplementary Materials)). As the biotransformation yields were monitored at each time point, the RSV metabolite reached its maximum yield after a day of incubation. Chemical analysis of the extract of the 1-day fermentation broth resulted in the isolation of a stilbene glycoside, named resvebassianol A (1) and RSV (Figure 1A) through semi-preparative HPLC purification.

Figure 1. (A) Chemical structures of resvebassianol A (1) and RSV (2). (B) Key 1H-1H COSY (blue bold lines) and HMBC (red arrows) correlations of 1. (C) Coupling constant analysis of 4-O-methyl-D-glucopyranose.

3.2. Structural Elucidation of Resvebassianol A (1)

Resvebassianol A (1) was isolated as a white amorphous powder and possessed a molecular formula of C21H23O8 as established by the HRESIMS ion at m/z 403.1395 [M–H]− (calculated for C21H23O8, 403.1393) and the NMR data (Table 1). The NMR data (Table 1) of 1 suggested that compound 1 shares the resveratrol skeleton by inspection and comparison of the NMR spectroscopic data with those of RSV [13], which was isolated in this study as compound 2. In addition, the signals of oxygenated protons were observed at δH 3.21 (1H, t, J = 9.0 Hz), 3.43 (1H, ddd, J = 9.0, 5.0, 2.0 Hz), 3.47 (1H, dd, J = 9.0, 8.0 Hz),
3.57 (1H, t, $J = 9.0$ Hz), 3.71 (1H, dd, $J = 12.0, 5.0$ Hz), 3.86 (1H, dd, $J = 12.0, 2.0$ Hz), and 4.90 (1H, d, $J = 8.0$ Hz), which was deduced to be attributable to the sugar unit together with the presence of a methoxyl group at $\delta_H 3.59 (3H, s)$. With the clear evidence of compound 1 being a resveratrol glycoside, the $^{13}$C NMR spectrum (Table 1) also showed the signals for the resveratrol frame and the rest of the carbon NMR resonances corresponding to the sugar unit at $\delta_C 102.2, 80.7, 78.1, 77.3, 75.1,$ and 62.2, and a methoxyl group at $\delta_C 61.1$. The proton at $\delta_H 4.90 (1H, d, \ J = 8.0$ Hz), attached to the downfield carbon at $\delta_C 102.2 (C-1''')$ with the aid of HSQC, was assigned to the anomeric proton, and its large $J$-value (8.0 Hz) was indicative of the $\beta$-oriented anomeric proton. A comprehensive investigation of the 2D NMR spectra of 1 allowed the establishment of its pyranose unit from C-1''' to C-6''' (Figure 1B) by $^1$H-$^1$H COSY correlations from H-1''' to H-6''' and HMBC correlation from methoxyl proton ($\delta_H 3.59$) to C-4''' ($\delta_C 80.7$). Based on this evidence and comparison of the NMR data of the sugar moiety in previous reports [14], the sugar unit was determined to be 4-O-methyl-$\beta$-glucopyranose. By the analysis of vicinal coupling constants of the sugar moiety ($J_{1''',2'''} = 8.0$ Hz, $J_{2''',3'''} = 9.0$ Hz, $J_{3''',4'''} = 9.0$ Hz, and $J_{4''',5'''} = 9.0$ Hz), it was confirmed that H-1''', H-2'''', H-3'''', H-4'''', and H-5'''' were all oriented in the axial positions of a pyranose ring (Figure 1C) [15]. The position of the sugar unit to the aglycone was determined by HMBC correlation between H-1''' and C-4' ($\delta_C 158.8$). The assignment of the D-configuration of the sugar unit was verified by the specific optical rotation value ($[\alpha]^{25}_D +27.5 \ (c 0.02, \ MeOH)$) of the sugar moiety obtained from the acid hydrolysate of 1, which was comparable to the 4-O-methyl-D-glucopyranose previously reported, $[\alpha]^{20}_D +71 \ (c 0.30, MeOH)$ [14]. Detailed analysis of COSY and HMBC correlations confirmed the complete structure of 1 as 4'''-O-(4''''-O-methyl-$\beta$-D-glucopyranosyl)-resveratrol, which we named resvebassianol A.

Interestingly, resvebassianol A is a glycosylated RSV with a unique sugar unit, 4-O-methyl-D-glucopyranose, and it is remarkable that natural products bearing the unique sugar moiety, including akanthol, meromusides A–B, and pyridovericin-N-O-glucopyranoside, were mostly isolated from entomopathogenic fungi [16–20]. Recently, the glycosyltransferase–methyltransferase (GT–MT) gene pair that encodes a methylglycosylation functional module has been identified in B. bassiana [21]. This GT–MT gene pair is unique to the entomopathogenic fungal species, leading to the characteristic methylglycosylated natural products of these organisms [21]. The GT–MT gene pair is promiscuous in conjugating methylglucose to a broad range of drug-like substrates, but it yields both O- and N-glucosides with substantial regio- and stereoselectivity. The resulting methylglycosylated products in the recent study included the production of resvebassianol A [21], yet the absolute configuration was established for the first time in the present study.

3.3. Microarray Analysis to Determine the Functional Differences between Resvebassianol A and RSV

We investigated the gene expression profiles of resvebassianol A- and RSV-treated skin keratinocytes using microarray analysis to determine the functional differences between resvebassianol A and RSV. Analyses of the gene expression data of both groups revealed 1790 differentially expressed genes with a fold-change higher than two. It was observed that 843 genes were upregulated, while 947 genes were downregulated in resvebassianol A-treated cells (Figure 2). The expression of several genes, including six upregulated genes and eight downregulated genes, was analyzed (Table 2).
Figure 2. Differential expression of genes in resvebassianol A- and RSV-treated keratinocytes. (A) Hierarchical clustering of altered mRNA. Microarray analysis for mRNA expression patterns of platelet heatmap of deregulated mRNAs, which were two-fold upregulated or downregulated. (B) Volcano plotting microarray analysis revealed the mRNAs that were two-fold upregulated or downregulated in platelet during storage.

Table 2. Upregulated or downregulated genes in resvebassianol A-treated keratinocytes compared to those in RSV-treated cells.

| Gene Symbol | RefSeq   | Gene Name                                      | Fold-Change |
|-------------|----------|------------------------------------------------|-------------|
| CCL17       | NM_002987| Chemokine (C-C motif) ligand 17                | 4.79        |
| FLG         | NM_002016| Filagrin                                       | 4.02        |
| HAS2-AS1    | NR_002835| HAS2 antisense RNA 1                           | 3.43        |
| IL17RE      | NM_153483| Interleukin 17 receptor E                      | 3.13        |
| TLR3        | NM_003265| Toll-like receptor 3                           | 3.00        |
| CERS3       | NM_178842| Ceramide synthase 3                           | 2.62        |
| IL11RA      | NM_001142784| Interleukin 11 receptor, alpha              | –2.24      |
| IL7R        | NM_002185| Interleukin 7 receptor                         | –2.62      |
| IL32        | NM_001012631| Interleukin 32                                    | –3.53      |
| IL1A        | NM_000575| Interleukin 1, alpha                           | –3.66      |
| CXCL8       | NM_000584| Chemokine (C-X-C motif) ligand 8               | –3.90      |
| IL23A       | NM_016584| Interleukin 23, alpha subunit p19              | –7.53      |
| IL4I1       | NM_152899| Interleukin 4 induced 1                        | –9.30      |
| IL11        | NM_000641| Interleukin 11                                 | –13.16     |

To further validate the results of microarray analyses, qRT-PCR was performed to confirm the expression of differentially expressed genes. The expression levels of many selected genes (FLG, HAS2-AS1, CERS3, IL23A, IL1A, and CXCL8) were examined via qRT-PCR using the same RNA samples. The expression levels of filaggrin (FLG), HAS2-AS1, and CERS3 were higher, while those of IL23A, IL1A, and CXCL8 were lower in the resvebassianol A-treated group than in the RSV-treated group. Thus, the results of qRT-PCR were consistent with those of the microarray analysis (Figure 3). The functions of these altered genes were mainly related to the maintenance of skin barrier function, immune reaction, and cell regeneration of keratinocytes derived from the skin epidermis.
Figure 3. The key differentially expressed mRNAs identified from microarray were verified using qRT-PCR. The expression of genes in resvebassianol A (1)- and RSV-treated groups was consistent with the results of gene chip detection. Values are expressed as means ± SD. * p < 0.05, ** p < 0.01, and *** p < 0.001 vs. RSV-treated group; Comp. means compound.

3.4. Effects of Resvebassianol A on the Proliferation and Migration of HaCaT Cells

Next, the proliferation effects of resvebassianol A were tested in HaCaT cells using the BrdU assay (Figure 4). Interestingly, resvebassianol A showed no cytotoxicity, whereas RSV showed cytotoxicity at 25 µM (Figure 4A). At the cellular and animal model levels, most glycosidic compounds are safer and have higher stability than aglycones. After comparing the proliferation rates of RSV and resvebassianol A, it was observed that the latter significantly inhibited cell proliferation from 24 h to 48 h, which was similar to the activity of RSV in IL-22-induced keratinocytes without any cytotoxicity (Figure 4B). To investigate the potential effects of resvebassianol A on cell migration and rejuvenation in skin keratinocytes, we performed a cell scratch assay and wound analysis. The wound areas in IL-22-induced HaCaT cells were measured after a 6 h treatment with resvebassianol A or RSV (1, 10 µM each, Figure 4C). Resvebassianol A inhibited cell migration; however, the same concentration of RSV showed higher inhibition (Figure 4C,D) in IL-22-induced HaCaT cells. The difference in proliferation and migration rates indicated that resvebassianol A showed effects similar to those of RSV without any cytotoxicity.

3.5. Inhibitory Effects of Resvebassianol A on the Inflammatory Cytokine Expression of TNF-α/INF-γ-Induced HIEC-6 Cells

To confirm the regenerative and anti-inflammatory effects of resvebassianol A in other tissues as well as in skin cells, we examined the inhibitory effects of resvebassianol A on inflammatory cytokine secretion in TNF-α/IFN-γ-stimulated HIEC-6 cells and human intestinal epithelial cells. Treatment with resvebassianol A showed no cell death, in contrast to RSV treatment (Figure 5A). Resvebassianol A significantly inhibited both IL-6 and IL-1β secretion in a dose-dependent manner, but the anti-inflammatory activity of RSV was higher than that of resvebassianol A (Figure 5B,C). These results suggest the inhibition of inflammatory cytokine secretion by resvebassianol A was similar to that of RSV with no cytotoxicity. Thus, resvebassianol A may maintain epithelial homeostasis and repair the damage caused by various toxic factors in skin and intestinal tissues. Based on these findings, resvebassianol A was determined to be safe for use even at high concentrations, unlike RSV, which is cytotoxic at high concentrations.
Figure 4. Effects of resvebassianol A on the proliferation and migration of HaCaT cells. (A) Cells were cultured in 96-well plates, and they were treated with resvebassianol A and RSV (1, 10, and 25 µM). After 24 h cell viability was measured using the MTT assay. (B) HaCaT cell proliferation after 24 and 48 h of treatment with resvebassianol A and RSV was measured using BrdU incorporation assay. (C) The wound margin was photographed after 0 h and 6 h of wound scratching. (D) Quantitative analysis of wound closure was determined as the wound area at a given time relative to that of the IL-22-treated group. Values are expressed as means ± SEM. **p < 0.01 and ***p < 0.001 versus untreated (control) group; *p < 0.05, **p < 0.01, and ***p < 0.001 vs. IL-22-treated group.

Figure 5. Inhibitory effects of resvebassianol A on the inflammatory cytokine expression of TNF-α/INF-γ-induced HIEC-6 cells. (A) Cells were cultured in 96-well plates, and they were treated with resvebassianol A and RSV at 1 and 10 µM, respectively. After 24 h, cell viability was measured using the MTT assay. (B,C) The levels of IL-6 and IL-1β in the supernatants were determined using ELISA. Values are expressed as means ± SD. ###p < 0.001 versus control group; *p < 0.05, **p < 0.01, and ***p < 0.001 vs. TNF-α/IFN-γ-treated group.
RSV has various biological activities in humans [22]. Particularly, many studies have reported the effectiveness of RSV in skin photoaging, inflammation, skin whitening, and skin cancer [23–26]. Despite its various biological functions, RSV has very low structural stability and bioavailability upon oral administration [27]. Additionally, it is known to interact with other drugs [28]. We have conducted several studies to investigate the application of RSV, its synthetic derivatives, and RSV-enriched rice as functional cosmeceuticals [23,29], where RSV showed cytotoxicity in skin cells at high concentrations. Therefore, we conducted this study to establish a new method for producing RSV derivatives using biotransformation on the entomopathogenic fungus *B. bassiana*, which led to the biosynthesis of an interesting RSV derivative with enhanced stability and safety. Glycosylation is widespread among natural products and is capable of increasing the diversity of structure and function of natural products [30]. Glycosylation of natural products can be advantageous in terms of water solubility, pharmacological activities, pharmacokinetic properties, and bioavailability [30], which provides useful information for the development and application of glycosylated natural products for drug research and development.

Recently, attempts were made to use the characteristic methylglycosylated natural products from *B. bassiana* for biosynthesis, where the resulting methylglycosylated products showed increased solubility and displayed increased stability against glycoside hydrolysis [21]. Upon methylglucosidation, specific methylglycosylated products were found to exhibit enhanced bioactivities [21]. These findings support our results establishing a new method for the biosynthesis of methylglycosylated RSV with enhanced safety and stability using biotransformation by *B. bassiana*.

4. Conclusions

In this study, we suggest a practical method for the efficient biosynthesis of a wide range of natural glycosides in total biosynthetic or biocatalytic platforms. Despite many trials for the development of a drug using RSV, there have been limitations associated with the metabolism and bioavailability of RSV. Our findings introduce the method for the production of a unique RSV metabolite, resvebassianol A, which is less toxic and has higher stability upon oral administration compared to RSV, while exhibiting the biological functions that RSV possesses. Until now, most studies on biotransformation have been intensively conducted on endogenous interactions using endophytes; instead, we used edible *B. bassiana* possessing excellent pharmacological activities in the skin and other diseases [20,21,31]. The current study will establish a foothold in successfully overcoming the problems in the development of RSV-derived drugs, while introducing an economically and ecologically friendly method for producing the RSV derivatives.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/biomedicines9050555/s1, Figure S1: HPLC analysis of RSV metabolites obtained from biotransformation of RSV by *B. bassiana*; Figure S2: The HR-ESIMS data of compound 1; Figure S3: The $^1$H NMR spectrum of compound 1 (CD$_3$OD, 700 MHz); Figure S4: The $^{13}$C NMR spectrum of compound 1 (CD$_3$OD, 175 MHz); Figure S5: The $^1$H–$^1$H COSY spectrum of compound 1; Figure S6: The HSQC spectrum of compound 1; Figure S7: The HMBC spectrum of compound 1.

Author Contributions: Conceptualization, I.C., K.H.K., and S.Y.K.; formal analysis, S.K.H., M.C.K., S.L., O.D., and D.S.; investigation, S.K.H., M.C.K., and S.L.; writing—original draft preparation, I.C., K.H.K., and S.Y.K.; writing—review and editing, K.H.K. and S.Y.K.; visualization, S.K.H., M.C.K., and S.L.; supervision, K.H.K. and S.Y.K.; project administration, I.C., K.H.K., and S.Y.K.; funding acquisition, K.H.K. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by a grant from the National Research Foundation of Korea (NRF), funded by the Korean government (MSIT) (2019R1A5A2027340 and 2021R1A2C2007937). This work was also supported by the Main Research Program (E0210203) of the Korea Food Research Institute (KFRI) funded by the Ministry of Science.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.
Conflicts of Interest: The authors declare no conflict of interest.

References

1. Xia, N.; Daiber, A.; Förstermann, U.; Li, H. Antioxidant effects of resveratrol in the cardiovascular system. Br. J. Pharmacol. 2017, 174, 1633–1646. [CrossRef]

2. Liu, M.; Tang, F.; Liu, Q.; Xiao, J.; Cao, H.; Chen, X. Inhibition of resveratrol glucosides (REs) on advanced glycation endproducts (AGEs) formation: Inhibitory mechanism and structure-activity relationship. Nat. Prod. Res. 2020, 34, 2490–2494. [CrossRef]

3. Rauf, A.; Imran, M.; Suleria, H.A.R.; Ahmad, B.; Peters, D.G.; Mubarak, M.S. A comprehensive review of the health perspectives of resveratrol. Food Funct. 2017, 8, 4284–4305. [CrossRef][PubMed]

4. Cottart, C.H.; Nivet-Antoine, V.; Laguillier-Morizot, C.; Beaudex, J.L. Resveratrol bioavailability and toxicity in humans. Mol. Nutr. Food Res. 2010, 54, 7–16. [CrossRef]

5. Gambini, J.; Inglez, M.; Olaso, G.; Lopez-Grueso, R.; Bonet-Costa, V.; Gimeno-Mallench, L.; Mas-Bargues, C.; Abdelaziz, K.M.; Gomez-Cabrera, M.C.; Borras, C. Properties of resveratrol: In vitro and in vivo studies about metabolism, bioavailability, and biological effects in animal models and humans. Oxid. Med. Cell. Longev. 2015, 2015, 837042. [CrossRef]

6. Howells, L.M.; Berry, D.P.; Elliott, P.J.; Jacobson, E.W.; Hoffmann, E.; Hegarty, B.; Brown, K.; Steward, W.P.; Gescher, A.J. Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases—Safety, pharmacokinetics, and pharmacodynamics. Cancer Prev. Res. 2011, 4, 1419–1425. [CrossRef]

7. de Carvalho, C.C.C.R.; da Fonseca, M.M.R. Biotransformation of terpenes. Biotechnol. Adv. 2000, 18, 134–142. [CrossRef]

8. Hu, X.; Liu, Y.; Li, D.; Feng, W.; Ni, H.; Cao, S.; Lu, F.; Li, Y. An innovative biotransformation to produce resveratrol by Bacillus safensis. RSC Adv. 2019, 9, 15448–15456. [CrossRef]

9. Cichewicz, R.H.; Kouzi, S.A.; Hamann, M.T. Dimerization of resveratrol by the grapevine pathogen Botrytis cinerea. J. Nat. Prod. 2000, 63, 29–33. [CrossRef]

10. Cichewicz, R.H.; Kouzi, S.A. Biotransformation of resveratrol to piceid by Bacillus cereus. J. Nat. Prod. 1998, 61, 1313–1314. [CrossRef]

11. Wang, L.; Wu, Y.; Chen, Y.; Zou, J.; Li, X. Biotransformation of resveratrol: New prenylated trans-resveratrol synthesized by Aspergillus sp. SC51002. Mol. Biol. 2016, 21, 883. [CrossRef]

12. Westwood, G.S.; Huang, S.-W.; Keyhani, N.O. Allergens of the entomopathogenic fungus Beauveria bassiana. Clin. Mol. Allergy 2005, 3, 1–8. [CrossRef][PubMed]

13. Sasikumar, P.; Lekshmy, K.; Sini, S.; Prabha, B.; Kumar, N.A.; Sivan, V.V.; Jithin, M.M.; Jayamurthy, P.; Shibi, I.G.; Radhakrishnan, R.V. Isolation and characterization of resveratrol oligomers from the stem bark of Hopea ponga (Dennst.) Mabb. and their antidiabetic effect by modulation of digestive enzymes, protein glycation and glucose uptake in L6 myocytes. J. Ethnopharmacol. 2019, 236, 196–204. [CrossRef][PubMed]

14. Isaka, M.; Haritakun, R.; Supothina, S.; Chouwong, W.; Mongkolsamrit, S. N-Hydroxypropyridone alkaloids, chromone derivatives, and tetrahydroxanthones from the scale-insect pathogenic fungus Orbiocrella sp. BCC 33248. Tetraheorden 2014, 70, 9198–9203. [CrossRef]

15. Bunyapaiboonsri, T.; Yoiprommarat, S.; Intereya, K.; Kocharin, K. New diphenyl ethers from the insect pathogenic fungus Cordyceps sp. BCC 1861. Chem. Pharrn. Bull. 2007, 55, 304–307. [CrossRef][PubMed]

16. Kuephadungphan, W.; Helaly, S.E.; Daengrot, C.; Phongpaichit, S.; Luangsa-Ard, J.J.; Rukachaisirikul, V.; Stadler, M. Akanthopyrones A–D, α-pyrones bearing a 4-α-methyl-β-glucopyranose moiety from the spider-associated Ascomycete Akanthomyces novoguineensis. Molecules 2017, 22, 1202. [CrossRef][PubMed]

17. Isaka, M.; Palasarn, S.; Supothina, S.; Komwijit, S.; Luangsa-Ard, J.J. Bioactive compounds from the scale insect pathogenic fungus Conioideocrella tenus BCC 18627. J. Nat. Prod. 2011, 74, 782–789. [CrossRef][PubMed]

18. Kornsakulkarn, J.; Thongpanchang, C.; Lapanun, S.; Srichomthong, K. Isocoumarin glucosides from the scale insect fungus Torruvbia tenus BCC 12732. J. Nat. Prod. 2009, 72, 1341–1343. [CrossRef]

19. Kornsakulkarn, J.; Saepua, S.; Srichomthong, K.; Supothina, S.; Thongpanchang, C. New mycoxotins from the scale insect fungus Aschersonia caffeaenn BCC 28712. Tetrahedron 2012, 68, 8480–8486. [CrossRef]

20. Zhang, L.; Fasoyin, O.E.; Molnari, I.; Xu, Y. Secondary metabolites from hypocrealean entomopathogenic fungi: Novel bioactive compounds. Nat. Prod. Rep. 2020, 37, 1186–1203. [CrossRef][PubMed]

21. Xie, L.; Zhang, L.; Wang, C.; Wang, X.; Xu, Y.-M.; Hu, Y.; Wu, P.; Li, S.; Han, L.; GunatiLaka, A.A.L.; et al. Methylglucosylation of aromatic amino and phenolic moieties of drug-like biosynthons by combinatorial biosynthesis. Proc. Natl. Acad. Sci. USA 2018, 115, E4980–E4989. [CrossRef][PubMed]

22. Fraczek, M.; Szumilo, J.; Podlodowska, J.; Burdan, F. Resveratrol—Phytopenol with wide activity. Pol. Merkur. Lek. Organ Pol. Tow. Lek. 2012, 32, 143–146.

23. Kang, M.C.; Cho, K.; Lee, J.H.; Subedi, L.; Yumnam, S.; Kim, S.Y. Effect of resveratrol-enriched rice on skin inflammation and pruritus in the NC/Nga mouse model of atopic dermatitis. Int. J. Mol. Sci. 2019, 20, 1428. [CrossRef]

24. Subedi, L.; Lee, T.H.; Wahedi, H.M.; Baek, S.H.; Kim, S.Y. Resveratrol-enriched rice attenuates UVB-ROS-induced skin aging via downregulation of inflammatory cascades. Oxid. Med. Cell. Longev. 2017, 2017, 8379539. [CrossRef]
25. Zhou, F.; Huang, X.; Pan, Y.; Cao, D.; Liu, C.; Liu, Y.; Chen, A. Resveratrol protects HaCaT cells from ultraviolet B-induced photoaging via upregulation of HSP27 and modulation of mitochondrial caspase-dependent apoptotic pathway. *Biochem. Biophys. Res. Commun.* 2018, 499, 662–668. [CrossRef]

26. Rauf, A.; Imran, M.; Butt, M.S.; Nadeem, M.; Peters, D.G.; Mubarak, M.S. Resveratrol as an anti-cancer agent: A review. *Crit. Rev. Food Sci. Nutr.* 2018, 58, 1428–1447. [CrossRef]

27. Chimento, A.; de Amicis, F.; Sirianni, R.; Sinicropi, M.S.; Puoci, F.; Casaburi, I.; Saturnino, C.; Pezzi, V. Progress to improve oral bioavailability and beneficial effects of resveratrol. *Int. J. Mol. Sci.* 2019, 20, 1381. [CrossRef]

28. Jia, Y.M.; Liu, Z.H.; Liu, K.X. Progress in regulation of drug transporters and metabolic enzymes by resveratrol. *Yao Xue Xue Bao Acta Pharm. Sin.* 2016, 51, 860–865.

29. Subedi, L.; Baek, S.H.; Kim, S.Y. Bioactive compounds of food: Their role in the prevention and treatment of diseases. *Oxid. Med. Cell. Longev.* 2018, 2018, 8092713.

30. Huang, G.; Lv, M.; Hu, J.; Huang, K.; Xu, H. Glycosylation and activities of natural products. *Mini Rev. Med. Chem.* 2016, 16, 1013–1016. [CrossRef]

31. Patocka, J. Bioactive metabolites of entomopathogenic fungi *Beauveria bassiana*. *Mil. Med. Sci. Lett.* 2016, 85, 80–88. [CrossRef]